Patent ID: 7871641

Claim:
A hepatocyte-targeting composition comprising: free glargine insulin; and glargine insulin associated with a water-insoluble target molecule complex; wherein said target molecule complex is comprised of a combination of a supra-molecular lipid construct matrix comprising at least one lipid component, and multiple linked individual units, each of said individual units comprising at least one bridging component selected from the group consisting of a transition element, an inner transition element, and a neighbor element of said transition element; and a complexing component; wherein said complexing component comprises at least one member selected from the group consisting of: N-(2,6-diisopropylphenylcarbamoylmethyl)iminodiacetic acid; N-(2,6-diethylphenylcarbamoylmethyl)iminodiacetic acid; N-(2,6-dimethylphenylcarbamoylmethyl)iminodiacetic acid; N-(4-isopropylphenylcarbamoylmethyl)iminodiacetic acid; N-(4-butylphenylcarbamoylmethyl)iminodiacetic acid; N-(2,3-dimethylphenylcarbamoylmethyl)iminodiacetic acid; N-(2,4-dimethylphenylcarbamoylmethyl)iminodiacetic acid; N-(2,5-dimethylphenylcarbamoylmethyl)iminodiacetic acid; N-(3,4-dimethylphenylcarbamoylmethyl)iminodiacetic acid; N-(3,5-dimethylphenylcarbamoylmethyl)iminodiacetic acid; N-(3-butylphenylcarbamoylmethyl)iminodiacetic acid; N-(2-butylphenylcarbamoylmethyl)iminodiacetic acid; N-(4-tertiary butylphenylcarbamoylmethyl)iminodiacetic acid; N-(3-butoxyphenylcarbamoylmethyl)iminodiacetic acid; N-(2-hexyloxyphenylcarbamoylmethyl)iminodiacetic acid; N-(4-hexyloxyphenylcarbamoylmethyl)iminodiacetic acid; aminopyrrol iminodiacetic acid; N-(3-bromo-2,4,6-trimethylphenylcarbamoylmethyl)iminodiacetic acid; benzimidazole methyl iminodiacetic acid; N-(3-cyano-4,5-dimethyl-2-pyrrylcarbamoylmethyl)iminodiacetic acid; N-(3-cyano-4-methyl-5-benzyl-2-pyrrylcarbamoylmethyl)iminodiacetic acid; and N-(3-cyano-4-methyl-2-pyrrylcarbamoylmethyl)iminodiacetic acid; provided that when said transition element is chromium, a chromium target molecule complex is created; wherein said target molecule complex further comprises a negative charge.